AzTrials
AzTrials

YogaSYNERGYNCT05031221

Feasibility and Impact of Yoga in Obesity

A study testing Yoga + behavioral weight loss in people with Yoga and Obesity, run by University of Colorado, Denver at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Yoga may confer health benefits in people with overweight or obesity that enhance weight loss and weight loss maintenance. This study aims to investigate the feasibility of integrating yoga into an established behavioral weight loss program and describe the effects on glucose control, appetite, dietary intake… Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Yoga, Obesity, Weight Loss
What is being tested?
Yoga + behavioral weight loss
Could I receive a placebo?
No, everyone receives an active treatment
How many people
21 participants
Where
1 siteUnited States
Study dates
2 Aug 2021to 15 Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Adults age 18-55
  • Body mass index (BMI) 27-45 kg/m2
  • Live or work within 30 miles of the University of Colorado Anschutz Health and Wellness Center
  • Passing medical and physical screening
  • Agree to fast for 12 hours before the baseline and follow-up visits
  • Sedentary: defined as <150 minutes per week of voluntary exercise at moderate intensity or greater and < 60 min per day of total habitual PA (i.e. work related, transportation related) at moderate intensity or greater, over the past 3 months.
Show all 9Show fewer
  • Not currently practicing yoga regularly over past 6 months
  • Among women: Not currently pregnant or lactating, not planning to become pregnant in the next 12 weeks
  • English speaking, as the intervention will be delivered in English

Who cannot join

  • Diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG
  • Resting heart rate >100
  • Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)
  • Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of uncontrolled thyroid disorder.
  • Abnormal values of: hematocrit, white blood cell count or platelets
  • Triglycerides > 400 mg/dL
Show all 24Show fewer
  • LDL cholesterol >200 mg/dL
  • Abnormal resting electrocardiogram (ECG)
  • Presence or history of any self-reported metabolic or chronic health problems which would affect appetite, food intake, energy metabolism, or ability to optimally participate in the exercise component
  • Significant self-reported pulmonary disorders including: chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.
  • Self-reported symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
  • Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, or energy metabolism
  • Regular use of systemic steroids (other than Oral Contraceptive Pills).
  • Regular use of obesity pharmacotherapeutic agents within the last 6 months.
  • Previous obesity treatment with surgery or weight loss device
  • Current alcohol or substance abuse
  • Nicotine use (past 6 months)
  • History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder.
  • Current severe depression or history of severe depression within the previous year
  • History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary or exercise interventions.
  • Currently participating in or planning to participate in any formal weight loss or physical activity programs or clinical trials.
  • Participation in a weight loss program using the Colorado Weigh curriculum within the past 3 years
  • Weight loss >5kg in past 3 months for any reason except post-partum weight loss
  • Weight loss of >50 lbs in past 3 years for any reason except post-partum weight loss.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Colorado - Anschutz Medical Campus

    Aurora, Colorado, 80045

Other trials in United States

About this study

Official title: A Proof-of-Concept Study Examining the Addition of Yoga to a Behavioral Weight Loss Intervention on Energy Balance and Health-Related Outcomes

Yoga may confer health benefits in people with overweight or obesity that enhance weight loss and weight loss maintenance. This study aims to investigate the feasibility of integrating yoga into an established behavioral weight loss program and describe the effects on glucose control, appetite, dietary intake, physical activity, and psychological health.

Read the detailed description

Innovative approaches to improve long-term behavioral weight loss (BWL) program outcomes are critically needed. Current BWL programs typically produce modest (~5-10%) short-term (~6 month) weight loss, but substantial weight regain by 1-year is common and well-documented. There has been a growing interest in examining the effects of yoga on weight loss and cardio-metabolic disease risk among adults with overweight, obesity, metabolic syndrome, pre-diabetes, and diabetes. Overall, results are somewhat promising, but reviews and meta-analyses all conclude that existing studies suffer from significant methodological shortcomings. Moreover, yoga is broadly, variably, and often incorrectly defined, reflecting how key aspects of traditional yoga practice, with specific mind, body, and breath-based practices were lost in translation when yoga was commercially adopted as a form of exercise in the West. These key aspects warrant inclusion in yoga intervention research.

The overall objectives of the proposed research are to 1) Evaluate the feasibility and acceptability of adding a 12-week traditional, multi-component yoga program to a standard BWL intervention (BWL+yoga), and 2) Explore changes in clinical/cardiometabolic, psychological, and energy balance/behavioral measures relevant for reducing cardio-metabolic disease risk. The yoga intervention was developed in collaboration with a world-renowned expert in traditional yoga practices following three decades of dedicated study, practice, and teaching (Mr. Paul Dallaghan). The program includes specific postures (asana), breathing (pranayama), and meditation (inner focus) techniques performed with an underlying focus on self-awareness delivered in-person and virtually. These specific techniques have been practiced historically and described for their benefits in the original Sanskrit teachings but are often excluded from yoga programs developed in the West. The overarching hypotheses are that these specific Hatha (body-breath) and Pantanjala (mind) yoga practices will be feasible in the context of a BWL, will support the adoption of changes in diet and physical activity, and improve mental and physical health.

Being tested
Yoga + behavioral weight loss
Medical subject headings
Obesity, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Yoga + behavioral weight lossBehavioural

    A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).

Study groups in NCT05031221
Study groupRoleWhat they receive
Yoga + behavioral weight lossExperimentalIn person and virtual yoga + 150 minutes of moderate-to-vigorous physical activity/week + weekly instruction on dietary strategies for weight loss
Receives: Behavioral: Yoga + behavioral weight loss

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Enrollment

    Ability to enroll 12-20 participants

    Measured: 12 weeks before intervention initiation

  2. Retention

    Attrition >20%

    Measured: At intervention completion (12 weeks)

  3. Collection of secondary outcome measures at baseline

    Percent completion of the cardiometabolic, psychological, and energy balance outcome measures

    Measured: Baseline (week 0)

  4. Collection of secondary outcome measures at follow-up

    Percent completion of the cardiometabolic, psychological, and energy balance outcome measures

    Measured: Intervention completion (12 weeks)

  5. Acceptability during the intervention

    Participant satisfaction with the intervention on a 1-10 Likert scale

    Measured: Week 6

  6. Acceptability after the intervention

    Participant satisfaction with the intervention on a 1-10 Likert scale

    Measured: Week 12

  7. Adherence

    Percent completion of intervention sessions

    Measured: Weekly during the 12 week intervention

  8. Adverse events (intervention safety)

    Study-related adverse events

    Measured: Weekly during the 12-week intervention

Secondary outcomes (6)
  1. Body weight change

    Body weight in kg

    Measured: Week 0 and 12

  2. Resting metabolic rate (RMR) change

    RMR in kcal/day

    Measured: Week 0 and 12

  3. Body composition change

    Fat mass and fat-free mass as measured by dual X-ray absorptiometry

    Measured: Week 0 and 12

  4. Glucose tolerance change

    2-hour oral glucose tolerance

    Measured: Week 0 and 12

  5. Cardiometabolic health change

    As measured by cholesterol, triglycerides, high- and low-density lipoproteins

    Measured: Week 0 and 12

  6. Heart rate variability change

    As measured by a 12-minute sit to stand protocol with heart rate monitor

    Measured: Week 0 and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2021
  2. Study start2 Aug 2021
  3. Primary completion15 Aug 2022
  4. Study completion15 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
Proof-of-Concept, single-arm study
Masking
None (open label)
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05031221
Sponsor's protocol ID
21-3690
Acronym
SYNERGY
Status last verified
Dec 2022
First submitted
29 Jul 2021
Last updated
22 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Yoga + behavioral weight loss in people with Yoga and Obesity, run by University of Colorado, Denver at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Enrollment (time frame: 12 weeks before intervention initiation). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in